Evidence map›Paper›PMID 26518158›Full record

Trial reportBMC gastroenterology2015

Xyloglucan for the treatment of acute diarrhea: results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial.

Lucio Gnessi, Vladimir Bacarea, Marius Marusteri, Núria Piqué

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
7.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 48 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Evaluation of Gelatin Tannate Against Symptoms of Acute Diarrhea in Pediatric Patients.Medical science monitor : international medical journal of experimental and clinical research · 2017
    Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Use of GELSECTANPatient preference and adherence · 2021
    Article
  19. Article
  20. Health Benefits of Heat-Killed (Tyndallized) Probiotics: An Overview.International journal of molecular sciences · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 3 countries.

Lucio GnessiDepartment of Experimental Medicine, University of Rome "La Sapienza", 00161, Rome, Italy. lucio.gnessi@uniroma1.it.
Vladimir BacareaDepartment of Epidemiology, University of Medicine & Pharmacy, Targu-Mures, Romania. bacarea@yahoo.com.
Marius MarusteriDepartment of Medical Informatics and Biostatistics, University of Medicine & Pharmacy, Targu-Mures, Romania. msmarusteri@yahoo.com.
Núria PiquéDepartment of Microbiology and Parasitology, Pharmacy Faculty, Universitat de Barcelona, Diagonal Sud, Facultat de Farmàcia, Edifici A, Av Joan XXIII, 08028, Barcelona, Spain. npique@gmail.com.
Universitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș · ROSapienza University of Rome · ITUniversitat de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is a strong rationale for the use of agents with film-forming protective properties, like xyloglucan, for the treatment of acute diarrhea. However, few data from clinical trials are available.

methodsA randomized, controlled, open-label, parallel group, multicentre, clinical trial was performed to evaluate the efficacy and safety of xyloglucan, in comparison with diosmectite and Saccharomyces in adult patients with acute diarrhea due to different causes. Patients were randomized to receive a 3-day treatment. Symptoms (stools type, nausea, vomiting, abdominal pain and flatulence) were assessed by a self-administered ad-hoc questionnaire 1, 3, 6, 12, 24, 48 and 72 h following the first dose administration. Adverse events were also recorded.

resultsA total of 150 patients (69.3 % women and 30.7 % men, mean age 47.3 ± 14.7 years) were included (n = 50 in each group). A faster onset of action was observed in the xyloglucan group compared with the diosmectite and S. bouliardii groups. At 6 h xyloglucan produced a statistically significant higher decrease in the mean number of type 6 and 7 stools compared with diosmectite (p = 0.031). Xyloglucan was the most efficient treatment in reducing the percentage of patients with nausea throughout the study period, particularly during the first hours (from 26 % at baseline to 4 % after 6 and 12 h). An important improvement of vomiting was observed in all three treatment groups. Xyloglucan was more effective than diosmectite and S. bouliardii in reducing abdominal pain, with a constant improvement observed throughout the study. The clinical evolution of flatulence followed similar patterns in the three groups, with continuous improvement of the symptom. All treatments were well tolerated, without reported adverse events.

conclusionsXyloglucan is a fast, efficacious and safe option for the treatment of acute diarrhea.

trial registrationEudraCT number 2014-001814-24 (date: 2014-04-28) ISRCTN number: 90311828.

Indexed as

Abdominal PainAdultDiagnostic Self EvaluationDiarrheaFecesFemaleFlatulenceGlucansHumansMaleMiddle AgedNauseaProbioticsSaccharomycesSilicatesTime FactorsGlucansSilicatesSmectiteXylansxyloglucan

Identifiers

PMID26518158
PMCPMC4628347
OpenAlexW1820755796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.